What is Kesimpta® (Ofatumumab) and how does it work? Kesimpta® contains the active ingredient ofatumumab. It is a self-administered therapy used for the treatment of adults with the relapsing forms of MS to delay the progression of physical disability and reduce the frequency of relapse.
Kesimpta (ofatumumab) is a disease modifying drug (DMD) for relapsing remitting MS. You take Kesimpta as an injection under the skin once a month. It reduces the number of relapses by about two thirds (70%).
For RMS patients, Kesimpta can be a very effective option with the convenience of self-administered monthly injections. It may be preferred over Ocrevus for those wanting to avoid infusions or with high Ocrevus copays. Frequent monitoring is not required.
For those patients who may not have prescription drug coverage, the list price for KESIMPTA is $9,347.07 per treatment. The list price may not reflect the price paid by patients; most patients with prescription coverage will pay less. *Limitations apply.
Further, 88.9% of treatment-naïve patients administered continuous Kesimpta were more likely to be free of progression independent of relapse activity events compared to 83.3% of those switching from Aubagio to Kesimpta.
“Our analysis of treatment-naïve people who were recently diagnosed with relapsing multiple sclerosis found that first-line use of Kesimpta for up to six years provided long-term benefits, including fewer relapses, profoundly suppressed MRI lesion activity, and fewer disability worsening events,” principal investigator ...
No, Kesimpta (ofatumumab) isn't chemotherapy. Chemotherapy works by killing fast-growing cells in the body. It's usually used to treat cancer. But Kesimpta (ofatumumab) is a type of medication called a monoclonal antibody.
Tecfidera, the newest pill treatment to enter the market, is also priced in the range of $62,000 per year. “MS DMDs are too expensive,” said Daniel Kantor, M.D., president of the Florida Society of Neurology, founder of the Southern MS Consortium. “This is almost universally recognized.
Ofatumumab (Kesimpta) destroys B cells so that there are fewer left to damage the myelin covering around your nerves. The drug reduces how much inflammation is seen on your MRI scans. Doctors can see this inflammation as lesions, areas of damage to nerves.
In clinical studies of patients who have been on Ocrevus for up to 10 years, 77% with relapsing MS were free from disability progression, and 92% continued to walk without needing assistance.
As well as disability benefits, there's other financial help out there that might make living with MS easier. Find out more about free public transport, disabled facilities grants, help with keeping warm in winter, prescription charges and dealing with debt.
The cause of multiple sclerosis is not known. It's considered an immune-mediated disease in which the body's immune system attacks its own tissues. In MS, the immune system attacks and destroys the fatty substance that coats and protects nerve fibers in the brain and spinal cord. This fatty substance is called myelin.
Dalfampridine is used to improve walking in people who have multiple sclerosis (MS; a disease in which the nerves do not function properly and may cause weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control).
Examples of live vaccines to avoid during Kesimpta treatment include: measles, mumps, rubella (MMR) chickenpox.
Personal Independence Payment (PIP)
You can spend it on whatever you need, such as paying for support to remain independent during relapses, or to help with extra costs such as heating, transport or help around the house. Some people with MS assume they can't get PIP because they're 'not disabled enough'.
Eating foods high in saturated fats can harm your health. Red meat and full-fat dairy products should be eaten less. They can cause inflammation, making MS symptoms worse. says, “Dietary changes can significantly impact the management of MS.”
Kesimpta and Ocrevus are both effective for relapsing MS, but Kesimpta may offer advantages in reducing relapse rates and MRI disease activity. Ocrevus remains the only option approved for primary progressive MS.
93% of Commercial patients in your area have first-line coverage for KESIMPTA® (ofatumumab). This includes patients enrolled in the following: 91% of Medicaid patients in your area have favorable coverage for KESIMPTA® (ofatumumab).
Antihistamines, such as diphenhydramine (Benadryl) and cetirizine (Zyrtec), are commonly used to manage allergies. However, these drugs can also make some MS-related symptoms worse.
Lifestyle and home remedies
It's an infusion you have every six months. To get it you must be early on in your primary progressive MS. Depending on your level of disability, 'early' means it's been between 10 and 15 years since your MS began.